The caspase selective inhibitor EP1013 augments human islet graft function and longevity in marginal mass islet transplantation in mice

Diabetes

Volumn 57, Issue 6, 2008, Pages 1556-1566

  Emamaullee, Juliet A ^a   Davis, Joy ^a   Pawlick, Rena ^a   Toso, Christian ^a   Merani, Shaheed ^a   Cai, Sui Xiong ^b   Tseng, Ben ^b   Shapiro, A M James ^a,c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Epicept   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLVALYLASPARTYL FLUOROMETHYL KETONE; CASPASE INHIBITOR; EP 1013; GLUCOSE; UNCLASSIFIED DRUG; BENZYLOXYCARBONYL VALYL ASPARTIC ACID FLUOROMETHYL KETONE; BENZYLOXYCARBONYL-VALYL-ASPARTIC ACID FLUOROMETHYL KETONE; C PEPTIDE; CASPASE; ENZYME INHIBITOR; HOMEODOMAIN PROTEIN; INSULIN; PEPTIDE CHLOROMETHYL KETONE; RAG 1 PROTEIN; RAG-1 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; ISOGRAFT; LONGEVITY; LOW DRUG DOSE; MOUSE; NONHUMAN; PANCREAS ISLET; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT DURATION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; GLUCOSE TOLERANCE TEST; GRAFT SURVIVAL; MOUSE MUTANT; PANCREAS ISLET TRANSPLANTATION; PHYSIOLOGY; SECRETION;

AMINO ACID CHLOROMETHYL KETONES; ANIMALS; C-PEPTIDE; CASPASES; ENZYME INHIBITORS; GLUCOSE; GLUCOSE TOLERANCE TEST; GRAFT SURVIVAL; HOMEODOMAIN PROTEINS; HUMANS; INSULIN; ISLETS OF LANGERHANS TRANSPLANTATION; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; TRANSPLANTATION, ISOGENEIC;

EID: 48249151829     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db07-1452     Document Type: Article

References (44)

1. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, Kneteman NM, Rajotte RV: Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 343:230-238, 2000
2. Shapiro AM, Ricordi C, Hering BJ, Auchincloss H, Lindblad R, Robertson RP, Secchi A, Brendel MD, Berney T, Brennan DC, Cagliero E, Alejandro R, Ryan EA, DiMercurio B, Morel P, Polonsky KS, Reems JA, Bretzel RG, Bertuzzi F, Froud T, Kandaswamy R, Sutherland DE, Eisenbarth G, Segal M, Preiksaitis J, Korbutt GS, Barton FB, Viviano L, Seyfert-Margolis V, Bluestone J, Lakey JR: International trial of the Edmonton protocol for islet transplantation. N Engl J Med 355:1318-1330, 2006
3. Robertson RP, Lanz KJ, Sutherland DE, Kendall DM: Prevention of diabetes for up to 13 years by autoislet transplantation after pancreatec- tomy for chronic pancreatitis. Diabetes 50:47-50, 2001
4. Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhli E, Kneteman NM, Lakey JR, Shapiro AM: Five-year follow-up after clinical islet transplantation. Diabetes 54:2060-2069, 2005
5. Emamaullee JA, Shapiro AM: Factors influencing the loss of beta-cell mass in islet transplantation. Cell Transplant 16:1-8, 2007
6. Ozmen L, Ekdahl KN, Elgue G, Larsson R, Korsgren O, Nilsson B: Inhibition of thrombin abrogates the instant blood-mediated inflammatory reaction triggered by isolated human islets: possible application of the thrombin inhibitor melagatran in clinical islet transplantation. Diabetes 51:1779-1784, 2002
7. Biarnes M, Montolio M, Nacher V, Raurell M, Soler J, Montanya E: β-Cell death and mass in syngeneically transplanted islets exposed to short- and long-term hyperglycemia. Diabetes 51:66-72, 2002
8. Davalli AM, Ogawa Y, Ricordi C, Scharp DW, Bonner-Weir S, Weir GC: A selective decrease in the beta cell mass of human islets transplanted into diabetic nude mice. Transplantation 59:817-820, 1995
9. Berney T, Mamin A, James Shapiro AM, Ritz-Laser B, Brulhart MC, Toso C, Demuylder-Mischler S, Armanet M, Baertschiger R, Wojtusciszyn A, Benhamou PY, Bosco D, Morel P, Philippe J: Detection of insulin mRNA in the peripheral blood after human islet transplantion predicts deterioration of metabolic control. Am, J Transplant 6:1704-1711, 2006
10. Emamaullee JA, Liston P, Korneluk RG, Shapiro AMJ, Elliott J: XIAP overexpression in islet beta-cells enhances engraftment and minimizes hypoxia-reperfusion injury. Am J Transplant 5:1297-1305, 2005
11. Emamaullee JA, Rajotte RV, Lakey JRT, Liston P, Korneluk RG, Shapiro AMJ, Elliott JF: XIAP Overexpression in human islets prevents early posttransplant apoptosis and reduces the islet mass needed to treat diabetes. Diabetes 54:2541-2548, 2005
12. Hui H, Khoury N, Zhao X, Balkir L, D'Amico E, Bullotta A, Nguyen ED, Gambotto A, Perfetti R: Adenovirus-mediated XIAP gene transfer reverses the negative effects of immunosuppressive drugs on insulin secretion and cell viability of isolated human islets. Diabetes 54:424-433, 2005
13. Emamaullee JA, Stanton L, Schur C, Shapiro AM: Caspase inhibitor therapy enhances marginal mass islet graft survival and preserves long- term function in islet transplantation. Diabetes 56:1289-1298, 2007
14. Montolio M, Tellez N, Biarnes M, Soler J, Montanya E: Short-term culture with the caspase inhibitor z-VAD.fmk reduces beta cell apoptosis in transplanted islets and improves the metabolic outcome of the graft. Cell Transplant 14:59-65, 2005
15. Nakano M, Matsumoto I, Sawada T, Ansite J, Oberbroeckling J, Zhang HJ, Kirchhof N, Shearer J, Sutherland DE, Hering BJ: Caspase-3 inhibitor prevents apoptosis of human islets immediately after isolation and improves islet graft function. Pancreas 29:104-109, 2004
16. Rozman-Pungercar J, Kopitar-Jerala N, Bogyo M, Turk D, Vasiljeva O, Stefe I, Vandenabeele P, Bromme D, Puizdar V, Fonovic M, Trstenjak-Prebanda M, Dolenc I, Turk V, Turk B: Inhibition of papain-like cysteine proteases and legumain by caspase-specific inhibitors: when reaction mechanism is more important than specificity. Cell Death Differ 10:881-888, 2003
17. Schotte P, Declercq W, Van Huffel S, Vandenabeele P, Beyaert R: Nonspecific effects of methyl ketone peptide inhibitors of caspases. FEBS Lett 442:117-121, 1999
18. Zhou YP, Sreenan S, Pan CY, Currie KP, Bindokas VP, Horikawa Y, Lee JP, Ostrega D, Ahmed N, Baldwin AC, Cox NJ, Fox AP, Miller RJ, Bell GI, Polonsky KS: A 48-hour exposure of pancreatic islets to calpain inhibitors impairs mitochondrial fuel metabolism and the exocytosis of insulin. Metabolism 52:528-534, 2003
19. Jaeschke H, Farhood A, Cai SX, Tseng BY, Bajt ML: Protection against TNF-induced liver parenchymal cell apoptosis during endotoxemia by a novel caspase inhibitor in mice. Toxicol Appl Pharmacol 169:77-83, 2000
20. Yang W, Guastella J, Huang JC, Wang Y, Zhang L, Xue D, Tran M, Woodward R, Kasibhatla S, Tseng B, Drewe J, Cai SX: MX1013, a dipeptide caspase inhibitor with potent in vivo antiapoptotic activity. Br J Pharmacol 140:402-412, 2003
21. Lakey JR, Warnock GL, Shapiro AM, Korbutt GS, Ao Z, Kneteman NM, Rajotte RV: Intraductal collagenase delivery into the human pancreas using syringe loading or controlled perfusion. Cell Transplant 8:285-292, 1999
22. Tsujimura T, Kuroda Y, Avila JG, Kin T, Oberholzer J, Shapiro AM, Lakey JR: Influence of pancreas preservation on human islet isolation outcomes: impact of the two-layer method. Transplantation 78:96-100, 2004
23. Ricordi C, Gray DW, Hering BJ, Kaufman DB, Warnock GL, Kneteman NM, Lake SP, London NJ, Socci C, Alejandro R, et al.: Islet isolation assessment in man and large animals. Acta Diabetol Lat 27:185-195, 1990
24. Barnett MJ, McGhee-Wilson D, Shapiro AM, Lakey JR: Variation in human islet viability based on different membrane integrity stains. Cell Transplant 13:481-488, 2004
25. Wang T, Singh B, Warnock GL, Rajotte RV: Prevention of recurrence of IDDM in islet-transplanted diabetic NOD mice by adjuvant immunotherapy. Diabetes 41:114-117, 1992
26. Davalli AM, Ogawa Y, Scaglia L, Wu YJ, Hollister J, Bonner-Weir S, Weir GC: Function, mass, and replication of porcine and rat islets transplanted into diabetic nude mice. Diabetes 44:104-111, 1995
27. Mellgren A, Schnell Landstrom AH, Petersson B, Andersson A: The renal subcapsular site offers better growth conditions for transplanted mouse pancreatic islet cells than the liver or spleen. Diabetologia 29:670-672, 1986
28. Yin D, Ding JW, Shen J, Ma L, Hara M, Chong AS: Liver ischemia contributes to early islet failure following intraportal transplantation: benefits of liver ischemic-preconditioning. Am J Transplant 6:60-68, 2006
29. Gruys ME, Back TC, Subleski J, Wiltrout TA, Lee JK, Schmidt L, Watanabe M, Stanyon R, Ward JM, Wigginton JM, Wiltrout RH: Induction of transplantable mouse renal cell cancers by streptozotocin: in vivo growth, metastases, and angiogenic phenotype. Cancer Res 61:6255-6263, 2001
30. Gray DW, Sutton R, McShane P, Peters M, Morris PJ: Exocrine contamination impairs implantation of pancreatic islets transplanted beneath the kidney capsule. J Surg Res 45:432-442, 1988
31. Migliavacca B, Nano R, Antonioli B, Marzorati S, Davalli AM, Di Carlo V, Bertuzzi F: Identification of in vitro parameters predictive of graft function: a study in an animal model of islet transplantation. Transplant Proc 36:612-613, 2004
32. Carlsson PO, Palm F, Mattsson G: Low revascularization of experimentally transplanted human pancreatic islets. J Clin Endocrinol Metab 87:5418-5423, 2002
33. Kin T, Zhai X, Murdoch TB, Salam A, Shapiro AM, Lakey JR: Enhancing the success of human islet isolation through optimization and characterization of pancreas dissociation enzyme. Am J Transplant 7:1233-1241, 2007
34. Hering BJ, Kandaswamy R, Ansite JD, Eckman PM, Nakano M, Sawada T, Matsumoto I, Ihm SH, Zhang HJ, Parkey J, Hunter DW, Sutherland DE: Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA 293:830-835, 2005
35. Hering BJ, Kandaswamy R, Harmon JV, Ansite JD, Clemmings SM, Sakai T, Paraskevas S, Eckman PM, Sageshima J, Nakano M, Sawada T, Matsumoto I, Zhang HJ, Sutherland DE, Bluestone JA: Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am J Transplant 4:390-401, 2004
36. Weir GC, Bonner-Weir S: Five stages of evolving β-Cell dysfunction during progression to diabetes. Diabetes 53 (Suppl. 3):S16-S21, 2004
37. Shapiro AM, Gallant HL, Hao EG, Lakey JR, McCready T, Rajotte RV, Yatscoff RW, Kneteman NM: The portal immunosuppressive storm: relevance to islet transplantation? Ther Drug Monit 27:35-37, 2005
38. Ryan EA, Paty BW, Senior PA, Shapiro AM: Risks and side effects of islet transplantation. Curr Diab Rep 4:304-309, 2004
39. Pockros PJ, Schiff ER, Shiffman ML, McHutchison JG, Gish RG, Afdhal NH, Makhviladze M, Huyghe M, Hecht D, Oltersdorf T, Shapiro DA: Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Hepatology 46:324-329, 2007
40. Baskin-Bey ES, Washburn K, Feng S, Oltersdorf T, Shapiro D, Huyghe M, Burgart L, Garrity-Park M, van Vilsteren FG, Oliver LK, Rosen CB, Gores GJ: Clinical trial of the pan-caspase inhibitor, IDN-6556, in human liver preservation injury. Am J Transplant 7:218-225, 2007
41. Valentino KL, Gutierrez M, Sanchez R, Winship MJ, Shapiro DA: First clinical trial of a novel caspase inhibitor: anti-apoptotic caspase inhibitor, IDN-6556, improves liver enzymes. Int J Clin Pharmacol Ther 41:441-449, 2003
42. Quadri SM, Segall L, de Perrot M, Han B, Edwards V, Jones N, Waddell TK, Liu M, Keshavjee S: Caspase inhibition improves ischemia-reperfusion injury after lung transplantation. Am J Transplant 5:292-299, 2005
43. Hoglen NC, Chen LS, Fisher CD, Hirakawa BP, Groessl T, Contreras PC: Characterization of IDN-6556 (3-[2-(2-tert-butyl-phenylaminooxalyl)-amino]- propionylamino]-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic acid): a liver-targeted caspase inhibitor. J Pharmacol Exp Ther 309:634-640, 2004
44. Martinon F, Tschopp J: Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ 14:10-22, 2007